Trial of Copaxone for primary-progressive MS.From 10 to 15 percent of people with MS never have attacks or relapses and never have remissions when their functions return and symptoms go away. Their MS just progressively gets worse, although there are times when it may plateau plateau, elevated, level or nearly level portion of the earth's surface, larger in summit area than a mountain and bounded on at least one side by steep slopes, occurring on land or in oceans. or stabilize stabilize See peg. . To date, there are no proven treatments for this form of the disease, which is called primary-progressive MS. None of the clinical trials of the A, B, or C drugs was designed to capture data on this type of MS. A new study, just begun, is changing that. On March 1, Teva Marion Marion. 1 City (1990 pop. 14,545), seat of Williamson co., S Ill.; inc. 1841. It is the commercial and retail center of a farm and coal area and has a large soft drink bottling plant. A maximum-security federal prison is nearby. Partners, distributors of Copaxone Copaxone® Glatiramer acetate, copolymer-1 Therapeutics A noninterferon, nonsteroidal agent that ↓ relapses in Pts with multiple sclerosis. See Multiple sclerosis. (glatiramer acetate glatiramer acetate (glahtear´a-meer as´  tāt),n a medication used to decrease or stop a relapse of multiple sclerosis. for injection), opened the largest-ever clinical trial for people with primary-progressive MS. The study asks if Copaxone will be safe for these individuals, and if it will slow or stop the progression of disability. This "gold standard" double-blind double blind n. A testing procedure, designed to eliminate biased results, in which the identity of those receiving a test treatment is concealed from both administrators and subjects until after the study is completed. placebo-controlled clinical trial is under the direction of Dr. Jerry Wolinksy of the University of Texas-Houston Health Science Center. In all, 54 MS centers in the U.S. and Canada are taking part, and some 900 volunteers with MS will be involved. People who have a confirmed diagnosis of primary-progressive MS and are willing to be part of a study are urged to discuss this with their physician. The volunteers may or may not receive Copaxone. No one will know who is getting the active drug until the trial is over. Information, including the list of centers conducting this trial, can be obtained by calling toll-free 1-877-758-7766, or by accessing this web site: www.promisetrial.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion